Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Lebanon Healthcare Journal.
Press releases published on July 23, 2025

Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress
– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership – – Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in …

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today …

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously …

Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provides further insight into its planned Phase 1 clinical trial of HemaXellerate, …

ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") today announced the closing of a private …

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President …

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
HOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates to …

Bio Usawa Biotechnology and ServareGMP Form Strategic Partnership to Advance Accessible Biotherapeutic Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology Ltd. (Bio Usawa) and ServareGMP (Servare) today announced a strategic partnership to establish advanced monoclonal antibody manufacturing capabilities …

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE …

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. …

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today …

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough …

Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025
WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research …

Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI
TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intracoronary imaging technologies, is pleased to highlight the recent publication in The American Journal of Cardiology titled “Regional …

dacadoo Forges Collaboration with Microsoft to Transform Digital Health Engagement in the Era of AI
Zurich, CH, July 23, 2025 (GLOBE NEWSWIRE) -- dacadoo, a global leader in digital health engagement …

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock
The trial will evaluate safety, dosing, and efficacy in patients with cardiogenic shock Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial …

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)- …

Cytovation to Advance Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling Under International Nonproprietary Name of Getacatetide
Plans to initiate Phase 2 clinical trial in Adrenocortical Carcinoma in early 2026 through unique partnership between Cytovation, Cancer Research UK and the Norwegian Cancer Society Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology …

Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product Officer Andreas Gerber …